CollPlant Biotechnologies (CollPlant Biotechnologies) Cash-to-Debt

: 8.44 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CollPlant Biotechnologies's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.44.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CollPlant Biotechnologies could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for CollPlant Biotechnologies's Cash-to-Debt or its related term are showing as below:

CLGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.98 Med: 11.09 Max: No Debt
Current: 8.44

During the past 12 years, CollPlant Biotechnologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.98. And the median was 11.09.

CLGN's Cash-to-Debt is ranked better than
53.28% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs CLGN: 8.44

CollPlant Biotechnologies Cash-to-Debt Historical Data

The historical data trend for CollPlant Biotechnologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CollPlant Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.05

0.98

12.00

10.19

8.44

CollPlant Biotechnologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															10.19	7.63	6.66	9.36	8.44

Competitive Comparison

For the Biotechnology subindustry, CollPlant Biotechnologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Cash-to-Debt falls into.

CollPlant Biotechnologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CollPlant Biotechnologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.674	/	(0.624	+	2.535)
	=	8.44

CollPlant Biotechnologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.674	/	(0.624	+	2.535)
	=	8.44

CollPlant Biotechnologies (NAS:CLGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CollPlant Biotechnologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.